News & Updates
Filter by Specialty:
Antibody cocktail may help relieve burden from hospitals
Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.
Antibody cocktail may help relieve burden from hospitals
21 Feb 2022Starting vedolizumab early better than late for UC
Starting vedolizumab early after the diagnosis of ulcerative colitis (UC) appeared more effective than delaying it to after initiation of other UC treatments, according to the RALEE study.
Starting vedolizumab early better than late for UC
21 Feb 2022Old age, unhealthy lifestyle weaken COVID-19 vaccine protection against severe illness
Vaccines provide the best defense against COVID-19, but they are not without limitations. Acute infections still occur in some, especially those who are older, smokers, obese, or with type 2 diabetes (T2D), as reported in a study.
Old age, unhealthy lifestyle weaken COVID-19 vaccine protection against severe illness
20 Feb 2022IM noninferior to IV sotrovimab for COVID-19
In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.
IM noninferior to IV sotrovimab for COVID-19
17 Feb 2022Tirofiban may improve outcomes in LAA strokes
While additional tirofiban prior to endovascular treatment (EVT) did not appear to benefit stroke patients with large vessel occlusion (LVO), it did seem to have an advantage for those with large artery atherosclerosis (LAA), findings from the RESCUE BT trial have shown.
Tirofiban may improve outcomes in LAA strokes
16 Feb 2022Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.